DE69936640D1 - Cannabinoiden als antioxidantien und neuroschützende mittel - Google Patents

Cannabinoiden als antioxidantien und neuroschützende mittel

Info

Publication number
DE69936640D1
DE69936640D1 DE69936640T DE69936640T DE69936640D1 DE 69936640 D1 DE69936640 D1 DE 69936640D1 DE 69936640 T DE69936640 T DE 69936640T DE 69936640 T DE69936640 T DE 69936640T DE 69936640 D1 DE69936640 D1 DE 69936640D1
Authority
DE
Germany
Prior art keywords
cannabinoids
useful
found
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936640T
Other languages
English (en)
Inventor
Aidan J Hampson
Julius Axelrod
Maurizio Grimaldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26767641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69936640(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69936640D1 publication Critical patent/DE69936640D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE69936640T 1998-04-21 1999-04-21 Cannabinoiden als antioxidantien und neuroschützende mittel Expired - Lifetime DE69936640D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8258998P 1998-04-21 1998-04-21
US9599398P 1998-08-10 1998-08-10
PCT/US1999/008769 WO1999053917A1 (en) 1998-04-21 1999-04-21 Cannabinoids as antioxidants and neuroprotectants

Publications (1)

Publication Number Publication Date
DE69936640D1 true DE69936640D1 (de) 2007-09-06

Family

ID=26767641

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936640T Expired - Lifetime DE69936640D1 (de) 1998-04-21 1999-04-21 Cannabinoiden als antioxidantien und neuroschützende mittel

Country Status (8)

Country Link
US (1) US6630507B1 (de)
EP (1) EP1071419B1 (de)
JP (1) JP2002512188A (de)
AT (1) ATE367809T1 (de)
AU (1) AU766988B2 (de)
CA (1) CA2329626A1 (de)
DE (1) DE69936640D1 (de)
WO (1) WO1999053917A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766988B2 (en) * 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants
AU3910700A (en) * 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
WO2001003690A1 (en) * 1999-07-12 2001-01-18 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
ES2444641T3 (es) * 2001-02-14 2014-02-26 Gw Pharma Limited Formulaciones líquidas para pulverización para liberación bucal de cannabinoides
CN1496271B (zh) 2001-02-16 2010-04-28 阿斯比奥制药株式会社 伴随有aop-1基因或aop-1的表达减少的疾病的治疗方法以及该疾病的治疗药
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
AU2002331595A1 (en) 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7285687B2 (en) * 2002-04-25 2007-10-23 Virginia Commonwealth University Cannabinoids
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
IL157849A0 (en) * 2003-09-10 2004-03-28 Yissum Res Dev Co Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives
US20060160748A1 (en) * 2003-11-25 2006-07-20 Shey-Shing Sheu Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
IL160420A0 (en) * 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
JP4569142B2 (ja) * 2004-03-22 2010-10-27 コニカミノルタホールディングス株式会社 表示素子
WO2006024958A2 (en) * 2004-08-09 2006-03-09 Novimmune S.A. Cannabinoid compositions and methods of use thereof
CA2589993C (en) * 2004-12-09 2012-07-03 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
US7597910B2 (en) * 2005-08-20 2009-10-06 Slgm Medical Research Institute Compositions and methods for treating prostate disorders
NZ567029A (en) * 2005-09-29 2011-09-30 Amr Technology Inc Process for production of delta-9- tetrahydrocannabinol
US20100158973A1 (en) * 2006-03-13 2010-06-24 Hadasit Medical Research Services & Development Llimited Therapeutic uses of cannabidiol compounds
NZ573217A (en) 2006-05-05 2011-11-25 Plascoenergy Ip Holdings S L Bilbao Schaffhausen Branch A facility for conversion of carbonaceous feedstock into a reformulated syngas containing CO and H2
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
RU2008152763A (ru) * 2006-06-08 2010-07-20 Ньюроки А/С (Dk) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
AU2007281918A1 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
US9763894B2 (en) * 2006-12-05 2017-09-19 Virginia Commonwealth University Inflammation therapy
WO2008107879A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel cannabidiol derivatives and their use as anti-inflammatory agents
US8242178B2 (en) * 2007-06-18 2012-08-14 University Of South Carolina Use of cannabidiol in the treatment of autoimmune hepatitis
GB2451254A (en) * 2007-07-24 2009-01-28 Gw Pharma Ltd Cannabidiol for use in the treatment of neurodegenerative conditions
JP2010535238A (ja) * 2007-07-30 2010-11-18 オールトランツ インコーポレイティド カンナビジオールのプロドラッグ、カンナビジオールのプロドラッグを含む組成物及びその使用方法
US20090181080A1 (en) * 2007-08-06 2009-07-16 Insys Therapeutics Inc. Oral cannabinnoid liquid formulations and methods of treatment
EP2341903A1 (de) * 2008-07-31 2011-07-13 Bionorica Research GmbH Cannabinoide zur behandlung oder prävention von kognitiver beeinträchtigung und demenz
US10105343B2 (en) 2010-04-30 2018-10-23 Kubby Patent And Licenses, Limited Liability Company Cannabis based compositions and methods of treating hypertension
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
US8642645B2 (en) 2011-05-20 2014-02-04 Brooks Kelly Research, LLC. Pharmaceutical composition comprising Cannabinoids
EP2934512B1 (de) 2012-12-18 2021-11-24 Kotzker Consulting LLC Verwendung von cannabinoiden und terpenen zur behandlung von organophosphat- und carbamattoxizität
US9095554B2 (en) 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
WO2014152385A2 (en) * 2013-03-15 2014-09-25 Glia, Llc Cranial delivery of pharmaceuticals
US10441617B2 (en) 2013-03-15 2019-10-15 Biotech Institute, Llc Breeding, production, processing and use of medical cannabis
US9763991B2 (en) 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
WO2015048508A1 (en) 2013-09-26 2015-04-02 Sekura Ronald D Topical treatments incorporating cannabis sp. derived botanical drug product
HRP20221172T1 (hr) 2013-10-29 2023-02-03 Biotech Institute, Llc Uzgoj, proizvodnja, prerada i uporaba specijalnog sinsemilla kanabisa
US10821240B2 (en) 2014-02-11 2020-11-03 Vapor Cartridge Technology Llc Methods and drug delivery devices using cannabis
US9220294B2 (en) 2014-02-11 2015-12-29 Timothy McCullough Methods and devices using cannabis vapors
US9380813B2 (en) 2014-02-11 2016-07-05 Timothy McCullough Drug delivery system and method
EP3119391A4 (de) 2014-03-18 2017-12-27 Izun Pharmaceuticals Corp. Proteingebundene cannabinoidzusammensetzungen
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
GB2527599A (en) * 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016010827A1 (en) 2014-07-14 2016-01-21 Librede Inc. Production of cannabinoids in yeast
US9565865B2 (en) 2014-08-15 2017-02-14 Imbue LLC Method for making coffee products containing cannabis ingredients
US10897915B2 (en) 2014-08-15 2021-01-26 Blacklist Holdings, Inc. Method for making coffee products containing cannabis ingredients
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EA201790880A1 (ru) 2014-10-21 2017-08-31 Юнайтед Кэннэбис Корп. Экстракты конопли и способы их получения и применения
US9539295B2 (en) 2014-12-05 2017-01-10 Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
WO2016105514A1 (en) 2014-12-23 2016-06-30 Biotech Institute, Llc A reliable and robust method for the analysis of cannabinoids and terpenes in cannabis
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US10830780B2 (en) 2015-01-26 2020-11-10 Biotech Institute, Llc Apparatus and methods for sample analysis and classification based on terpenes and cannabinoids in the sample
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
EP3302033A4 (de) 2015-05-28 2018-10-31 Tweed Inc. Cannabispflanzen mit modifizierter expression der thca-synthase
JP2018534362A (ja) * 2015-10-16 2018-11-22 スキティアン バイオサイエンシーズ インコーポレーテッドＳｃｙｔｈｉａｎ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． 外傷性脳損傷を処置するための方法および組成物
CN109311838A (zh) * 2016-04-15 2019-02-05 蒂温诺特技术有限公司 大麻素前药的生物合成
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2017218853A1 (en) 2016-06-15 2017-12-21 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress
WO2018035030A1 (en) * 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CA3048841A1 (en) 2016-12-30 2018-07-05 X Traxion, Llc Extraction of compounds from cannabis
US10960322B2 (en) 2018-07-02 2021-03-30 Pratt Bethers Apparatus for purifying crystals using solvent vapors
US10308626B1 (en) 2018-07-02 2019-06-04 Pratt Bethers Crystal purification in a glass or metal container
US10561693B2 (en) 2017-09-01 2020-02-18 MariJ Pharmaceuticals, Inc. Cultivation, processing, and synthesis of cannabidiols
EP3453397A1 (de) 2017-09-12 2019-03-13 Albert Jan Dijkstra Verfahren zur isolierung eines cannabinoidextrakts und produkt aus cannabispflanzenmaterial
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
US11407724B2 (en) * 2018-08-20 2022-08-09 Bessor Pharma, Llc Process for the production of cannabinoids
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
US20220106284A1 (en) * 2019-03-04 2022-04-07 University Of Florida Research Foundation, Inc. Methods and compositions for substituted axially-chiral cannabinol analogs
AU2020270175A1 (en) 2019-05-06 2021-12-02 The University Of British Columbia Antibiotic cannabinoid-terpene formulations
EP3997069A4 (de) * 2019-07-12 2023-07-12 Canopy Growth Corporation Cannabinoidderivate
MX2022003189A (es) 2019-09-16 2022-06-08 Vapor Cartridge Tech Llc Sistema de administración de fármacos con sustratos apilables.
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201916974D0 (en) * 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
WO2021155390A1 (en) * 2020-01-14 2021-08-05 Shaman Naturals, Llc. Antimicrobial compositions
CA3074150A1 (en) 2020-02-18 2021-08-18 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
WO2021245671A1 (en) * 2020-06-03 2021-12-09 Epm (Ip), Inc. Cannabidiolic acid (cbda) derivatives and uses thereof
GB2597302A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
AU2021318553A1 (en) 2020-07-28 2023-03-23 Impello Biosciences Inc. Methods and compositions for altering secondary metabolites in plants
JP2023553335A (ja) 2020-11-24 2023-12-21 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド カンナビノイド誘導体、及び、炎症、疼痛又は肥満の治療におけるそれらの使用
CN112516119A (zh) * 2021-02-05 2021-03-19 云南维他源生物科技有限公司 一种治疗脑卒中的asbd药物组合物及其制剂与应用
WO2022238707A1 (en) * 2021-05-12 2022-11-17 GW Research Limited Rescorcinols, methods for their manufacture, and uses thereof
AU2022272860A1 (en) * 2021-05-12 2023-11-30 GW Research Limited Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof
WO2023285072A1 (en) 2021-07-13 2023-01-19 Receptorpharma Inc S-Corp Esters of 7-cooh cbd derivatives and their use as prevention, prophylaxis of progression, and/or treatment of neurogenerative diseases.
CN113735709B (zh) * 2021-09-17 2022-03-18 中国农业科学院农产品加工研究所 一种大麻二酚-2-丁酸酯及其应用
CN116253700A (zh) * 2021-12-10 2023-06-13 德义制药有限公司 一种大麻二酚衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
IL80411A (en) 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5521215A (en) * 1989-11-07 1996-05-28 Ramot University Authority For Applied Research And Industrial Development Ltd. NMDA-blocking pharmaceuticals
US5284867A (en) 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
IL92238A (en) * 1989-11-07 1995-07-31 Yissum Res Dev Co ADMN blocking product containing tetrahydrocannabinol history, several new tetrahydrocannabinol histories and process for their preparation
ATE157249T1 (de) 1990-03-16 1997-09-15 Us Health Stickoxide zur gewichtsreduktion
DE4100441A1 (de) 1991-01-09 1992-07-16 Mack Chem Pharm Verfahren zur herstellung von 6,12-dihydro-6-hydroxy-cannabidiol und dessen verwendung zur herstellung von trans-delta-9-tetrahydrocannabinol
US5538993A (en) 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
IL99468A (en) 1991-09-12 1997-09-30 Yissum Res Dev Co (3s, 4s)-delta- 6-tetrahydrocannabinol- 7-oic acids and derivatives thereof, processes for their preparation and pharmaceutical compositions containing them
US5635530A (en) 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
WO1994012667A1 (en) 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage
US5696109A (en) 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
CA2102142A1 (en) 1993-03-30 1994-10-01 Andrew J. Ghio Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
FR2714057B1 (fr) 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5434295A (en) 1994-02-07 1995-07-18 Yissum Research Development Company Neuroprotective pharmaceutical compositions of 4-phenylpinene derivatives and certain novel 4-phenylpinene compounds
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
IT1271267B (it) 1994-12-14 1997-05-27 Valle Francesco Della Ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
FR2741621B1 (fr) 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
GB9807639D0 (en) 1998-04-14 1998-06-10 Kennedy Rheumatology Inst Anti-inflammatory agents
AU766988B2 (en) * 1998-04-21 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cannabinoids as antioxidants and neuroprotectants

Also Published As

Publication number Publication date
AU3864699A (en) 1999-11-08
ATE367809T1 (de) 2007-08-15
AU766988B2 (en) 2003-10-30
US6630507B1 (en) 2003-10-07
CA2329626A1 (en) 1999-10-28
EP1071419B1 (de) 2007-07-25
EP1071419A1 (de) 2001-01-31
JP2002512188A (ja) 2002-04-23
WO1999053917A1 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
DE69936640D1 (de) Cannabinoiden als antioxidantien und neuroschützende mittel
HRP20050735A2 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
MY133406A (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as a medicament
AP1422A (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
AR029634A1 (es) Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento
EE200100317A (et) Uued bifenüül- ja bifenüülanaloogsed ühendid kui integriini antagonistid
YU4397A (sh) Novi supstituisani oksazolidinoni
DE69908819D1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
HUP0400998A2 (hu) Új gyulladásgátló, immunmodulátor és antiproliferatív hatású vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
IL123002A0 (en) 1-Phenyl-2- phenylacetoxy- ethanone derivatives
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
DE602004006994D1 (en) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
MXPA04000814A (es) Derivados de 2h-piridazina-3-ona novedosos, composiciones farmaceuticas que contienen a los mismos y un procedimiento para la preparacion del ingrediente activo.
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
ES2168304T3 (es) Derivados del taxol.
YU56302A (sh) Derivati 8,8a-dihidro-indeno/1,2-d/taizola, koji su supstituisani u 8a-položaju,postupak za njihovu proizvodnju i njihova primena kod leka npr.kao anorektičnog sredstva
ES2243579T3 (es) Derivados de pirazolopirideno.
TW200505865A (en) Compounds useful for the treatment of diseases
ES2036926A1 (es) "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.

Legal Events

Date Code Title Description
8332 No legal effect for de